Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation

International Journal of Neuropsychopharmacology

Volumn 16, Issue 1, 2013, Pages 121-135

  MacDowell, Karina S ^a,b,c   García Bueno, Borja ^a,b,c   Madrigal, José L M ^a,b,c   Parellada, Mara ^b,d   Arango, Celso ^b,d   Micó, Juan A ^b,e   Leza, Juan C ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c Instituto de Investigación Sanitaria Hospital ^*  (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSITY OF CÁDIZ   (Spain)

Author keywords

Antipsychotics; LPS; neuroinflammation; risperidone; schizophrenia

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN SYNTHASE; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFECT; LIPID PEROXIDATION; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENCEPHALITIS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, WISTAR; RISPERIDONE; UP-REGULATION;

EID: 84871518090     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001775     Document Type: Article

References (68)

1. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, et al. (2007). Celecoxib as adjunctive therapy in schizophrenia : a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 90, 179-185.
2. Allan SM, Rothwell NJ (2003). Inflammation in central nervous system injury. Philosophical Transactions of the Royal Society B: Biological Sciences 358, 1669-1677.
3. Arolt V, Rothermundt M, Wandinger KP (2000). Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry 5, 150-158.
4. Bechter K (2004). The mild encephalitis-hypothesis-new findings and studies. Psychiatrische Praxis 31, 41-43.
5. Bian Q, Kato T, Monji A, Hashioka S, et al. (2008). The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-c. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 42-48.
6. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72, 248-254.
7. Dantzer R, O'Connor JC, Freund GG, Johnson RW, et al. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Review Neuroscience 9, 46-56.
8. Das I, Khan NS (1998). Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins, Leukotrienes and Essential Fatty Acids 58, 165-168.
9. Das NP, Ratty AK (1987). Studies on the effects of the narcotic alkaloids, cocaine, morphine and codeine on nonenzymatic lipid peroxidation in rat brain mitochondria. Biochemical Medicine and Metabolic Biology 37, 256-264.
10. Dean B (2010). Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders : evidence from human peripheral studies and CNS studies. International Journal of Neuropsychopharmacology 15, 1-16.
11. Dietrich-Muszalska A, Kontek B (2010). Lipid peroxidation in patients with schizophrenia. Psychiatry and Clinical Neurosciences 64, 469-475.
12. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J (2005). Oxidative stress in blood platelets from schizophrenic patients. Platelets 16, 386-391.
13. Dremencov E, El Mansari M, Blier P (2007a). Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berlin) 194, 63-72.
14. Dremencov E, El Mansari M, Blier P (2007b). Noradrenergic augmentation of escitalopram response by risperidone : electrophysiologic studies in the rat brain. Biological Psychiatry 61, 671-678.
15. Drexhage RC, Padmos RC, de Wit H, Versnel MA, et al. (2008). Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? Schizophrenia Research 102, 352-355.
16. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, van Beveren N, et al. (2010). Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. International Journal of Neuropsychopharmacology 13, 1369-1381.
17. Forman BM, Chen J, Evans RM (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences USA 94, 4312-4317.
18. Galea E, Heneka MT, Dello Russo C, Feinstein DL (2003). Intrinsic regulation of brain inflammatory responses. Cellular and Molecular Neurobiology 2, 625-635.
19. GarcÍa-Bueno B, Caso JR, Leza JC (2008a). Stress as a neuroinflammatory condition in brain : damaging and protective mechanisms. Neuroscience and Biobehavioural Reviews 32, 1136-1151.
20. GarcÍa-Bueno B, Caso JR, Perez-Nievas BG, Lorenzo P, et al. (2007). Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 32, 1251-1260.
21. GarcÍa-Bueno B, Madrigal JL, Lizasoain I, Moro MA, et al. (2005). Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biological Psychiatry 57, 885-894.
22. GarcÍa-Bueno B, Madrigal JL, Perez-Nievas BG, Leza JC (2008b). Stress mediators regulate brain prostaglandin synthesis and peroxisome proliferator-activated receptor-gamma activation after stress in rats. Endocrinology 149, 1969-1978.
23. Gerard C, Bruyns C, Marchant A, Abramowicz D, et al. (1993). Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. Journal of Experimental Medicine 177, 547-550.
24. Gonzalez-Scarano F, Baltuch G (1999) Microglia as mediators of inflammatory and degenerative diseases. Annual Review of Neurosciences, 22, 219-240.
25. Green LC, Wagner DA, Glogowski J, Skipper PL, et al. (1982). Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Analytical Biochemistry 126, 131-138.
26. Hanson DR, Gottesman II (2005). Theories of schizophrenia : a genetic-inflammatory-vascular synthesis. BMC Medical Genetics 11, 6-7.
27. Heneka MT, Landreth GE (2007). PPARs in the brain. Biochemical and Biophysical Acta 1771, 1031-1045.
28. Himmerich H, Schonherr J, Fulda S, Sheldrick AJ, et al. (2011). Impact of antipsychotics on cytokine production in-vitro. Journal of Psychiatry Research 45, 1358-1365.
29. Hou Y, Wu CF, Yang JY, He X, et al. (2006). Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide- activated N9 cells. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30, 1523-1528.
30. Houseknecht KL, Cole BM, Steele PJ (2002). Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domestic Animal Endocrinology 22, 1-23.
31. Howard M, Muchamuel T, Andrade S, Menon S (1993). Interleukin 10 protects mice from lethal endotoxemia. Journal of Experimental Medicine 177, 1205-1208.
32. Huang TL, Liou CW, Lin TK (2010). Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients : effects of antipsychotic drugs. Psychiatry Research 177, 18-21.
33. Kaiya H, Uematsu M, Ofuji M, Nishida A, et al. (1989). Elevated plasma prostaglandin E2 levels in schizophrenia. Journal of Neural Transmission 77, 39-46.
34. Kapadia R, Yi JH, Vemuganti R (2008). Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in Biosciences 13, 1813-1826.
35. Kato T, Monji A, Hashioka S, Kanba S (2007). Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophrenia Research 92, 108-115.
36. Kato TA, Monji A, Mizoguchi Y, Hashioka S, et al. (2011). Anti-inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? Mini-Reviews in Medicinal Chemistry 11, 565-574.
37. Leykin I, Mayer R, Shinitzky M (1997). Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 37, 75-86.
38. Lucas SM, Rothwell NJ, Gibson RM (2006). The role of inflammation in CNS injury and disease. British Journal of Pharmacology 147, S232-S240.
39. McNamara RK, Jandacek R, Rider T, Tso P (2011). Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats. European Journal of Pharmacology 652, 152-156.
40. Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, et al. (1996). Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia : effects of antipsychotic drugs. Schizophrenia Research 2, 39-50.
41. Mahadik SP, Mukherjee S (1996). Free radical pathology and antioxidant defense in schizophrenia : a review. Schizophrenia Research 19, 1-17.
42. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, et al. (1998). Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biological Psychiatry 43, 674-679.
43. ÍÍÍ MartÍnez-Gras I, Perez-Nievas BG, GarcÍa-Bueno B, Madrigal JL, et al. (2011). The anti-inflammatory prostaglandin 15d-PGJ(2) and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophrenia Research 128, 15-22.
44. Mico JA, Rojas-Corrales MO, Gibert-Rahola J, Parellada M, et al. (2011). Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry. Published online: 14 February 2011. doi :10.1186/1471-244X-11-26.
45. Monji A, Kato T, Kanba S (2009). Cytokines and schizophrenia : microglia hypothesis of schizophrenia. Psychiatry and Clinical Neuroscience 63, 257-265.
46. Muller N, Empl M, Riedel M, Schwarz M, et al. (1997) Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. European Archives of Psychiatry and Clinical Neurosciences 247, 308-313.
47. Muller N, Schwarz MJ (2008) A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. European Archives of Psychiatry and Clinical Neurosciences 258, 97-106.
48. Muller N, Schwarz MJ (2010). Immune system and schizophrenia. Current Immunological Review 6, 213-220.
49. Naiker DV, Catts SV, Catts VS, Bedi KS, et al. (2006). Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. European Journal of Pharmacology 540, 87-90.
50. Olsen CK, Brennum LT, Kreilgaard M (2008). Using pharmacokinetic- pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. European Journal of Pharmacology 584, 318-327.
51. Padurariu M, Ciobica A, Dobrin I, Stefanescu C (2010). Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neuroscience Letters 479, 317-320.
52. Pall HS, Williams AC, Blake DR, Lunec J (1987). Evidence of enhanced lipid peroxidation in cerebrospinal fluid of patients taking phenothiazines. Lancet 2, 596-599.
53. Potvin S, Stip E, Sepehry AA, Gendron A, et al. (2008). Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 63, 801-808.
54. Reale M, Patruno A, de Lutiis MA, Pesce M, et al. (2011). Dysregulation of chemo-cytokine production in schizophrenic patients vs. healthy controls. BMC Neurosciences 12, 13.
55. Robertson SA, Skinner RJ, Care AS (2006). Essential role for IL-10 in resistance to lipopolysaccharide-induced preterm labor in mice. Journal of Immunology 177, 4888-4896.
56. Saetre P, Emilsson L, Axelsson E, Kreuger J, et al. (2007). Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 7, 46.
57. Salter M, Duffy C, Garthwaite J, Strijbos PJ (1996). Ex vivo measurement of brain tissue nitrite and nitrate accurately reflects nitric oxide synthase activity in vivo. Journal of Neurochemistry 66, 1683-1690.
58. Schreiber E, Matthias P, Muller MM, Schaffner W (1989). Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Research 17, 6419.
59. Serhan CN, Brain SD, Buckley CD, Gilroy DW, et al. (2007). Resolution of inflammation : state of the art, definitions and terms. FASEB Journal 21, 325-332.
60. Song C, Lin A, Kenis G, Bosmans E, Maes M (2000). Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophrenia Research 42, 157-164.
61. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP (2009). The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biological Psychiatry 65, 481-488.
62. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, et al. (2001). Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berlin) 158, 140-145.
63. Steiner J, Bielau H, Brisch R, Danos P, et al. (2008). Immunological aspects in the neurobiology of suicide : elevated microglial density in schizophrenia and depression is associated with suicide. Journal of Psychiatric Research 42, 151-157.
64. Sugino H, Futamura T, Mitsumoto Y, Maeda K, et al. (2009). Atypical antipsychotics suppress production of pro-inflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Progress in Neuropsychopharmacology and Biological Psychiatry 33, 303-307.
65. van Berckel BN, Bossong MG, Boellaard R, Kloet R, et al. (2008). Microglia activation in recent-onset schizophrenia : a quantitative (R)-[11C]PK11195 positron emission tomography study. Biological Psychiatry 64, 820-822.
66. Volk DW, Lewis DA (2010). Prefrontal cortical circuits in schizophrenia. Current Topics in Behavioral Neuroscience 4, 485-508.
67. Watanabe Y, Someya T, Nawa H (2010). Cytokine hypothesis of schizophrenia pathogenesis : evidence from human studies and animal models. Psychiatry Clinical Neurosciences 64, 217-230.
68. Yao JK, Reddy R, McElhinny LG, van Kammen DP (1998). Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophrenia Research 32, 1-8.